Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775361 | 0.98 | LPAR3 (0.40) | LPAR3LPAR2TSHRALDH1A1 | |
| SCHEMBL4778227 | 0.94 | ALDH1A1 (0.32) | LPAR3LPAR2TSHRALDH1A1 | |
| SCHEMBL22856412 | 0.85 | CA2 (0.32) | — | |
| SCHEMBL1164717 | 0.79 | TSHR (0.39) | LPAR3LPAR2TSHRALDH1A1 | |
| SCHEMBL4780400 | 0.76 | — | — | |
| SCHEMBL25722783 | 0.74 | TSHR (0.58) | TSHRALDH1A1 | |
| SCHEMBL4778272 | 0.74 | ALDH1A1 (0.31) | LPAR3LPAR2TSHRALDH1A1 | |
| SCHEMBL11303860 | 0.73 | — | — | |
| SCHEMBL31408699 | 0.73 | — | — | |
| SCHEMBL4775373 | 0.72 | TSHR (0.35) | LPAR3LPAR2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008004788-A1 | NOVEL DERIVATIVES OF CYCLIC COMPOUND AND THE USE THEREOF | WONKISOPHARM CO., LTD. (KR) | 2008-01-10 | — | — | WO | claimed |
| US-8252846-B2 | Strategies for delivery of active agents using micelles and particles | EMORY UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100062968-A1 | Novel strategies for delivery of active agents using micelles and particles | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2010-03-11 | — | — | US | disclosed |
| US-20090011993-A1 | Novel strategies for delivery of active agents using micelles and particles | GEORGIA TECH RESEARCH CORPORATION | 2009-01-08 | — | — | US | disclosed |
| WO-2008004788-A1 | NOVEL DERIVATIVES OF CYCLIC COMPOUND AND THE USE THEREOF | WONKISOPHARM CO., LTD. (KR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090011993-A1 | Novel strategies for delivery of active agents using micelles and particles | CD47, CHMP4B, MASP2 | LPAR3 138/4885LPAR2 235/4885TSHR 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.